T his statement of the Committee on Advanced Cardiac Imaging and Technology of the Council on Clinical Cardiology addresses the use of positron emission tomography (PET) as a clinical tool for the diagnosis and management of patients with coronary artery disease. Over the past decade PET technology has evolved to the point that clinical PET studies can be performed safely and efficiently in the evaluation of patients with known or suspected coronary artery disease. Two specific uses of PET in management of coronary artery disease have been proposed: 1) noninvasive detection of coronary artery disease and estimation of its severity and 2) assessment of myocardial viability in patients with coronary artery disease and left ventricular dysfunction. The diagnostic use of PET would apply to a large number of patients, whereas its use to assess myocardial viability would apply to a smaller, more select number of patients.
As of February 1991, the available data that have emerged from the few centers with sufficient experience in cardiac PET indicate that this promising and advanced imaging modality can often provide accurate information in both of these clinical situations. PET allows more sensitive data acquisition than single photon emission computed tomography (SPECT). In addition, coincidence detection provides a means of measuring tissue photon attenuation for subsequent correction of emission data. In clinical practice, such attenuation correction results in improved delineation of regional tracer concentration compared with current SPECT methods. Present-generation whole-body PET scanners provide multislice capabilities (up to 31 tomographic levels simultaneously) with an in-plane "Cardiac Positron Emission Tomography" was approved by the American Heart Association Steering Committee on February 14, 1991. Requests for reprints should be sent to the Office of Scientific Affairs, American Heart Association, 7320 Greenville Avenue, Dallas, TX 75231. spatial resolution of 5-10 mm. In comparison, the resolution of tomographic thallium-201 studies using SPECT is approximately 15-20 mm. However, PET is an expensive technology that, if widely implemented, could increase overall cardiovascular health care costs. To date, only a few studies, involving small numbers of patients, have directly compared the results of PET with those of more readily available, less expensive modalities that may also be used clinically to detect coronary disease, estimate its severity, and determine myocardial viability. Thus, there are limited data that may be used to assess the cost-effectiveness of PET relative to standard, more readily available imaging modalities, particularly in studies in which expertise in both PET and standard single photon imaging are comparable in the same investigators' institution.
Detection and Estimation of Severity of

Coronary Artery Disease
Myocardial Perfusion Imaging With Positron
Emission Tomography
The diagnosis of coronary artery disease by PET is based on evaluation of regional myocardial blood flow with myocardial perfusion tracers. The most commonly used tracers are rubidium-82, ammonia labeled with nitrogen-13, and water labeled with oxygen-15. 82Rb (half-life 75 seconds) is generator produced, whereas the use of [13N]ammonia (half-life 10 minutes) and ['50]water (half-life 2 minutes) require on-site cyclotrons. The short half-lives of these agents allow sequential examinations, such as rest-exercise or rest-dipyridamole studies, within a short time frame that is not possible with standard perfusion imaging using 2o1Tf.
The relation between blood flow and regional uptake of either 82Rb or [13N]ammonia is not linear, and at high flow rates, either agent will underestimate regional blood flow.1'2 Thus, the nonlinear responses of 82Rb and [13N]ammonia extraction to increases in blood flow limit their use in obtaining quantitative flow measurements to estimate severity of coronary artery stenoses. In addition, attempts to quantify flow with either 82Rb or ['3N]ammonia are compounded by other factors. "Rb is considered a potassium analogue, and myocardial uptake of "Rb may reflect active cation transport processes across the sarcolemma as well as blood flow; myocardial incorporation of ["N]ammonia into radiolabeled amino acids must be accounted for in any mathematical model used to compute flow with ["N]ammonia.3 These problems can be circumvented by appropriate modeling of the myocardial extraction of ['3N]ammonia,4-6 and animal studies suggest that this may be possible with "Rb as well.7
In contrast to ['3N]ammonia and "Rb, [`O]water is a freely diffusible perfusion tracer, and accurate measurement of absolute myocardial blood flow is possible across a wide range of flow values. Absolute regional myocardial blood flow in humans has been calculated noninvasively,8 with animal validation studies as the basis. However, cardiac images after injection of [`50]water include the oxygen-15 activity of both the right and left ventricular blood pools as well as myocardial activity; myocardial perfusion images can be obtained only after subtraction of the blood pool activity by another positron agent (such as carbon monoxide labeled with carbon-11 or oxygen-15), which may be difficult in a clinical environment. This subtraction process also results in images of lower resolution than those obtained using either 8"Rb or [13N]ammonia.
The capacity to determine quantitative regional myocardial blood flow noninvasively is unique to PET. Such estimates could be useful in the clinical setting in assessing the efficacy of angioplasty and detecting diffuse abnormalities of myocardial perfusion reserve, such as those that might occur in left ventricular hypertrophy, in the transplanted heart, or in syndrome X. Although the theoretical and practical limitations of obtaining quantitative blood flow measurements appear to be surmountable, most centers rely on qualitative or only semiquantitative interpretation of 8"Rb or [13N]ammonia images for diagnosis of coronary artery disease and estimation of its severity (i.e., the hemodynamic significance of a coronary stenosis). Exercise studies with short-lived PET perfusion tracers are difficult, and chest motion during exercise will impair both image quality and attenuation correction, so most studies have used pharmacological vasodilator stress with intravenous dipyridamole or adenosine to assess relative regional myocardial blood flow and flow reserve.
Diagnosis of Coronary Artery Disease
Numerous studies, each involving a small number of patients, indicate that perfusion imaging by PET with either 8"Rb or ['3N]ammonia identifies abnormal blood flow reserve in most patients with coronary artery disease,9 '3 suggesting that PET may be a highly sensitive and specific clinical tool for diagnosis of coronary artery disease. In one of two large published studies, Demer et al14 compared qualitative assessment of regional myocardial flow reserve by PET with coronary flow reserve calculated from quantitative coronary arteriography in 193 patients. In this study, either "Rb or [13N]ammonia images were obtained at rest and after the combination of dipyridamole-hand grip stress. The defect score measured by PET was scaled subjectively from 0 (normal) to 5 (severely abnormal). The PET score correlated significantly with the flow reserve data derived from quantitative coronary arteriography for each of 243 coronary stenoses, although the correlation was not very high (r=0.63). As might be expected with qualitative estimates of flow reserve, when the most severe defect detected by PET was compared with the flow reserve measured for the most severe stenosis, the correlation was higher (r=0.77). Demer et al14 did not report the sensitivity and specificity of PET in detecting coronary artery disease in their population. However, analysis of their Figure 3 shows that a PET score of grade 2 or more had a sensitivity of approximately 95% and a specificity of approximately 74% in identifying patients with reduced flow reserve by quantitative angiography (defined as a flow reserve of less than 3). This is consistent with sensitivity and specificity values in this same patient population reported in an earlier abstract (94% and 77%, respectively).15 When a higher threshold was chosen to define normal flow reserve by quantitative arteriography (flow reserve greater than or equal to 4), a higher specificity (95%) resulted. 15 As with any increase in normal threshold values resulting in increased specificity, it must be anticipated that a higher specificity will be achieved at the expense of a substantial reduction in sensitivity. According to the data in the abstract,15 the threshold resulting in a specificity of 95% was associated with abnormal results in 125 of 152 patients with coronary artery disease, yielding a sensitivity of 82%.
In the other large investigation, Go et al16 studied 202 patients with coronary arteriography and "2Rb PET, using dipyridamole-hand grip stress. These investigators reported a PET sensitivity of 93% in the detection of coronary artery disease and a specificity of 78%, results quite similar to those of Demer et al.1415 When patients who had undergone previous revascularization procedures were excluded, sensitivity and specificity were 95% and 82%, respectively.16
Reproducibility of Measurements
Considering the relative flow measurements made with either "2Rb or ["N]ammonia PET, it appears that the measurements should be sufficiently reproducible, with little intraobserver and interobserver variability. This has been the case for interobserver variability. In the study by Demer et al,14 there was agreement between two observers about scoring the defects as detected by PET within two grades in 82% of rest studies and 83% of studies obtained during combined dipyridamole-hand grip stress. The two observers agreed in 89% of patients regarding the presence (grade 2 or higher) or absence (grade less than 2) of significant perfusion defects detected by PET. Intraobserver variability was not reported. Preliminary data from Mody et al17 showed significantly greater interobserver variability between three observers in the qualitative interpretation of ["N]ammonia images, with no important intraobserver variability.
Comparison With 20`T1 Scintigraphy PET has several theoretical advantages over 201 studies in the accurate identification of patients with coronary artery disease: PET provides higher resolution images with intrinsic collimation. The higher energy photons released from positron-emitting tracers and routine attenuation correction procedures overcome photon attenuation problems commonly encountered in 201T1 studies. However, in the first published paper comparing PET perfusion studies with exercise 201T1 scintigraphy in the same patients, the results were remarkably similar. 12 Tamaki et al studied 51 patients (48 had coronary artery disease) by exercise`01T1 SPECT and PET performed with dipyridamole and ["N]ammonia. The sensitivity of 201T1 SPECT (96%) in identifying ischemia in patients with coronary artery disease was similar to that of PET (98%). Specificity in detecting disease could not be addressed because only three patients did not have coronary artery disease. Tamaki and colleagues also investigated the relative abilities of SPECT and PET to identify significant stenoses of individual coronary arteries. Again, the SPECT data (81% sensitivity and 94% specificity) compared favorably with the PET data (88% sensitivity and 90% specificity). Results of the PET studies were not significantly different in any vascular area from those of the SPECT studies.
Investigators at a second institution16 compared 20MT1 SPECT with 82Rb PET, using a single dipyridamole-hand grip stress for both imaging agents. They found improved diagnostic accuracy with 82Rb PET, results which stemmed primarily from lower sensitivity in the detection of coronary artery disease with 201T1 SPECT (76%) than with 82Rb PET (95%). The low sensitivity of 201T1 may be related in part to the timing of dipyridamole administration, because 82Rb was given at the peak dipyridamole effect, and`0'TI was given at least 6 minutes after the peak effect. It is also noteworthy that more than 75% of the falsenegative 201Tl SPECT studies that were correctly diagnosed on the 82Rb PET studies involved the inferior and posterior wall, a region with greater interpretative errors with 201Tl SPECT because of true or perceived photon attenuation. Although this is a known limitation of 201Tl imaging, the two examples of false-negative 201T1 SPECT studies shown in Figures 4 and 5 of the paper by Go et al16 might be interpreted by other observers as 201T1 perfusion defects (i.e., true-positive findings). Preliminary findings from a third institution'8 revealed similar sensitivities between 201T1 SPECT (using exercise or dipyridamole) and 82Rb PET (using dipyridamole-hand grip) in identifying coronary artery disease (90% and 87%, respectively) and identifying individual coronary artery stenoses (65% and 64%, respectively). It is important to note that in this study, PET'had higher specificity than SPECT both in diagnosis of patients (82% and 57%, respectively) and of individual coronary artery stenosis (92% and 84%, respectively). This could represent evidence of enhanced diagnostic accuracy of PET because of fewer interpretative errors related to photon attenuation. However, the low specificity of the '01T1 SPECT results in this study compared with previous 01T1 SPECT results raises the possibility that patient selection factors, such as a posttest referral bias (using an initial abnormal '01T1 test as the indication for subsequent coronary arteriography and PET), could be operative.
Summary and Recommendations
PET imaging with 82Rb or ["N]ammonia provides clinically useful and accurate measures of regional myocardial blood flow for the sensitive and specific detection and localization of coronary artery disease. The diagnostic accuracy of PET is at least equivalent to that of 20MT1 scintigraphy, and recent data suggest that PET may provide diagnostic accuracy greater than that of 20'T1 SPECT.16,l8 However, widespread clinical use of PET for this purpose could have profound effects on cardiovascular health care costs. Whether the incremental cost of PET is justified by the possible improvement in diagnostic accuracy has not been established. It is the opinion of the committee that the data are not yet available to demonstrate a clear superiority of PET over other currently accepted, more readily available, and less expensive techniques for the routine diagnosis of coronary artery disease or for determining the functional significance of coronary stenosis in patients with established coronary artery disease. The committee recognizes that PET provides valuable information in certain individual clinical situations, such as patients with equivocal 2`TlI SPECT results related to questions of photon attenuation or patients whose physical characteristics are likely to raise issues of photon attenuation. The committee also recognizes that the emerging technetium-99m-based perfusion agents may be superior to 211T1 in the diagnosis of coronary artery disease,'9 are less likely to produce attenuation artifacts, and use standard gamma camera equipment already in place in most nuclear cardiology laboratories.
Assessment of Myocardial Viability
Left ventricular dysfunction in patients with coronary artery disease is not always an irreversible process stemming from myocardial necrosis or fibrosis, because regional and global left ventricular function will improve in many patients, at times markedly, after coronary revascularization. Until recently, an accurate assessment of myocardial viability often could be performed only retrospectively, after the patient had undergone revascularization. Pro-spective detection of viable myocardium by PET in such patients is based on the demonstration of intact metabolic activity in regions of severely underperfused and dysfunctional myocardium.
Positron Emission Tomography Agents
[18F]Fluorodeoxyglucose. This agent (FDG) has been used as a marker of regional exogenous glucose utilization to detect viable myocardium in such hypoperfused regions.20-26 In particular, a pattern of enhanced FDG uptake in regions with reduced perfusion (termed the FDG-blood flow mismatch) indicates ischemic or hibernating myocardium that has shifted its metabolic substrate preference toward glucose and away from fatty acids or lactate.
Maintained or enhanced use of glucose, as estimated by the increased regional uptake of FDG relative to blood flow, has been an accurate clinical marker for distinguishing viable myocardium from myocardial fibrosis. Both Tillisch et a122 and Tamaki et a126 studied a small number of patients (17 and 22, respectively) with left ventricular dysfunction who underwent surgical revascularization. In these investigations, preoperative identification of metabolic activity in regions with reduced myocardial blood flow (assessed qualitatively by ['3N]ammonia PET) was associated with improved postoperative function in 78-85% of regions. In contrast, improved regional function after revascularization occurred in only 8-22% of regions in which metabolic activity was not demonstrable before surgery. Thus, evidence of preserved metabolic activity in myocardial regions with reduced blood flow in these two studies had a positive predictive accuracy of 78-85% in identification of viable myocardium and a negative predictive accuracy of 78-92%. Changes in global left ventricular ejection fraction after surgery were reported in only one of these studies. 22 Patients with intact metabolic activity (with normal or increased FDG uptake) in regions with reduced perfusion had a significant improvement in ejection fraction, from a mean of 30% before operation to 45% afterward; in contrast, patients in whom metabolic activity was absent in hypoperfused regions had no change in ejection fraction (30% before and 31% after operation). Although each of these studies included only a small number of patients, a relatively large number of myocardial regions with resting wall motion abnormalities were evaluated (79 and 46, respectively). These studies demonstrated that metabolic imaging with PET is a promising method for identification of viable myocardium in patients with coronary artery disease and left ventricular dysfunction.
Because regional uptake of metabolic tracers such as FDG is sensitive to overall metabolic state, rigid standardization of the metabolic environment is necessary to maximize the amount of diagnostic information obtained by this technique. Application of PET imaging with FDG in patients with diabetes mellitus requires normalization of plasma glucose levels and insulin therapy. However, despite improvement of image quality using this approach, there are no data validating the predictive value of FDG uptake for tissue viability in this patient population.
['1C]Acetate. This agent has recently emerged as another promising agent for use in PET studies of myocardial viability. Regional uptake and clearance of ['1C]acetate is directly related to regional oxidative metabolism, and quantitative analysis of [11C]acetate kinetics may be used as a noninvasive means of calculating myocardial oxygen consumption and oxidative metabolic reserve. [27] [28] [29] [30] Preliminary studies indicate that preserved oxidative metabolism as estimated by [11C]acetate kinetics in regions of reduced coronary blood flow is a marker of myocardial viability both in chronic coronary artery disease31'32 and after acute myocardial infarction. [33] [34] [35] 82Rb. Reversible and irreversible ischemic tissue injury may also be determined with 82Rb since uptake and retention of this agent is dependent on both coronary blood flow and cell membrane integrity. In regions of myocardial fibrosis, the diminished uptake of 82Rb reflects a reduction in perfusion that is more severe than in regions of dysfunctional but viable myocardium. In the setting of acute myocardial injury, uptake of 82Rb occurs if blood flow is restored, but leakage of 82Rb from necrotic tissue follows its initial uptake, resulting in a perfusion defect. In addition to net uptake, the kinetics of this ion leak may be used as an index of myocardial viability. [36] [37] [38] Recent data indicate that such an analysis may provide clinical information comparable to that achieved by PET imaging with FDG in patients with acute myocardial infarction.38
Comparison With 20'T1 Scintigraphy
The ability to define regional metabolic activity (and hence provide metabolic evidence of viable myocardium) by PET is unique. However, as noted above, imaging agents that reflect cation flux, such as 82Rb and 201Ti, may also provide clinically relevant information regarding myocardial viability. Because 20flT scintigraphy is more readily available than PET and is also less costly, it is important to compare the results of 2`TI imaging with those of metabolic PET imaging in identifying viable myocardium in the same patient population. Four published studies, two by Brunken The results of these comparative studies should be viewed in light of the previous experience of standard exercise-redistribution 201T1 imaging in detecting viable compared with scarred myocardium. "Irreversible" 20`TI defects on exercise-redistribution 201T1 studies overestimate the frequency and severity of myocardial fibrosis; between 25% and 50% of patients with apparently irreversible 20`Tl defects have normal 201T1 uptake and improved regional left ventricular function after revascularization.4344 Thus, standard exercise-redistribution 201T1 imaging appears to result in reduced predictive accuracy in identifying viable myocardium, compared with the results of PET imaging discussed previously.
This has been the case in studies by Brunken et a13940 and Tamaki These data indicate that metabolic imaging using PET methods is superior to standard exercise-redistribution 201T1 scintigraphy in detection of viable myocardium in patients with left ventricular dysfunction.
Limitations of Comparative Studies
All four of these comparative studies involved small numbers of patients. Brunken et al reported data in only 12 patients in the initial study using planar 201T1 imaging techniques39 and in 26 patients in the later 20`TI SPECT analysis. 40 Tamaki et al41,42 also studied small numbers of patients (22 and 28, respectively) and it is possible that at least some of the same patients were included in both reports. None of the four studies included an independent standard of viability, such as improvement in wall motion after revascularization. There are two additional issues regarding analysis of the 20NT1 SPECT results in these four studies. First, the severity of the irreversible 201T1 defects was not considered in comparison with regional FDG activity. The level of relative 201T1 activity within irreversible defects may reflect tissue viability.44-46 Second, postexercise 201T1 imaging was used in all four studies and followed by only a single redistribution study [3] [4] 
hours later. Late 2077 Redistribution Imaging
It is now well established that late imaging at 8-72 hours will demonstrate substantial 201T1 redistribution in many defects that appear to be irreversible at [3] [4] hours, and that late 201`1 uptake is consistent with viable myocardium.47-49 Of note, the number of "irreversible" defects at 3-4 hours that subsequently show reversal on late imaging (22-54%) is in some studies similar to the frequency of metabolic activity demonstrated by PET 45 This study involved only 16 patients, and the effect of revascularization on regional or global left ventricular function was not investigated. Thus, these data require confirmation by a larger series before definitive conclusions can be drawn. It is noteworthy that preliminary findings from another institution55 comparing FDG uptake with 201T1 uptake after reinjection in 14 patients have provided concordant data.
Additional preliminary data suggest that 201T1 injected under resting conditions may also provide important information about myocardial viability in patients with left ventricular dysfunction.56 Summary and Recommendations Although the amount of published data is limited, PET appears to provide clinically useful and accurate estimates of myocardial viability in patients with coronary artery disease, regional or global left ventricular dysfunction, and regional hypoperfusion.
PET provides a noninvasive means of identifying patients with coronary artery disease and left ventricular dysfunction who, on the basis of metabolic evidence of viability in the myocardial territory to be revascularized, may be candidates for coronary artery bypass surgery or angioplasty. PET also identifies patients (those without metabolic activity) in whom there is little chance for improvement in regional and global left ventricular function after revascularization and in whom the risks of revascularization may therefore not be justified.
The committee recommends that PET be used to assess relative regional metabolic activity with FDG in patients in whom myocardial viability is in question, but only in those patients in whom the identification of viable myocardium is an important clinical issue that will lead to changes in management, such as a decision regarding revascularization. Patients with coronary artery disease and regional or global left ventricular dysfunction are candidates for metabolic imaging with PET, particularly those in whom evidence of regional viability on a 20`TI perfusion study is equivocal.
The committee also recognizes and emphasizes that there are new insights regarding the use of 201T1 scintigraphy, including the use of resting 201T1 injections or exercise studies with 201T1 reinjection and/or late redistribution imaging, that hold promise. Comparative data in small numbers of patients suggest that 201T1 imaging may provide most of the clinically relevant data regarding viable myocardium in patients with left ventricular dysfunction. If this initial experience with 201T1 is confirmed by larger patient series, it may become reasonable, from the perspective of health care cost containment, to recommend that PET studies be performed only if an initial 201T1 study does not provide conclusive results.
The new 9'Tc perfusion agents may also be useful in detection of viable myocardium. Firm recommendations about the roles of 201T1 scintigraphy, 99mTc perfusion agents, or PET in identifying viable myocardium must await the results of definitive comparative studies. Implementation of multicenter trials comparing PET with conventional techniques for the definition of tissue viability, using standardized data acquisition and analysis, are recommended for objective assessment of the clinical efficacy of metabolic PET imaging.
